Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Linhui Peng
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06172205CT.gov Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | — | Recruiting | — | — | — |
NCT03777124CT.gov Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03393507CT.gov A Study of Apatinib Treatment in for Advanced Ovarian Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Toxicity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | Linhui Peng | P3 | B · 62 |
| Dexasone | Instituto do Cancer do Estado de São Paulo | P4 | A |
| Palonosetron | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | A |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Netupitant | Instituto Brasileiro de Controle do Cancer | P3 | BB |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BB |
| HR20013 | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Endeavor Health | P3 | BB |
| Ondansetron | Dr Atul Sharma | P3 | BB |
+42 more in the Chemotherapy-Induced Toxicity cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DexasoneInstituto do Cancer do Estado de São PauloA
- PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityA
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- NetupitantInstituto Brasileiro de Controle do CancerBB
- DocetaxelThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBB
Citation
Floatz Terminal. Rivoceranib in Chemotherapy-Induced Toxicity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-chemotherapy-induced-toxicity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →